NeonMind Files for U.S. Provisional
Patent to Use Psychedelic-Assisted Psychotherapy for Weight
Loss
Vancouver, British Columbia -- June 4, 2020 -- InvestorsHub
NewsWire -- The Yield Growth Corp. (CSE: BOSS) (OTCQB: BOSQF) (FSE: YG3) announces that
its majority owned subsidiary NeonMind, on June 3, 2020 filed a
U.S. provisional patent application in the United States for the
invention relating to therapeutic administration of psilocybin or
psilocin (or analogs thereof) ("Psilocybin")
combined with supportive therapeutic treatment for a patient to
provide weight loss benefits and treatment for related health
issues.
Figure 1: NeonMind Files for U.S. Provisional Patent to Use
Psychedelic-Assisted Psychotherapy for Weight Loss
The provisional patent is for a proposed guided
psychedelic psilocybin therapy protocol using psychotherapy prior
to, during and after the psychoactive effects of the Psilocybin are
felt by the patient. The psychedelic assisted psychotherapy is
designed to assist in gaining insights from positive psychedelic
experiences, to be integrated into everyday life and to help plan,
prepare and make sense of psychedelic experiences for a therapeutic
result. It can include an exploration of unresolved issues in the
patient's life that are embedded in his or her subconscious,
including discussions or examinations of pain. It may also include
building self-esteem, the patient taking responsibility for his or
her own condition, self empowerment, and acknowledging or releasing
any unhealthy self defence mechanism of overeating.
NeonMind previously announced that it filed a
provisional patent in December 2019 for the use of microdose
administration of Psilocybin for weight loss benefits. NeonMind has
retained contract research organization Translational Life Sciences
Inc. to design and plan an initial preclinical study using
psilocybin which is anticipated to begin in the fall of 2020. The
preclinical study is anticipated to provide data to design phase 2
human clinical trials to test Psilocybin as a weight loss
treatment. The phase 2 clinical trials are anticipated to begin in
2021, subject to receiving all required regulatory approvals.
NeonMind's combined provisional patent applications
cover the administration of Psilocybin to provide weight loss
benefits and potential treatment or regulation of diabetes, and
regulation of blood glucose, and to reduce susceptibility to
cardiovascular disease, high blood pressure, diabetes mellitus,
hypertension, multiple sclerosis, erectile dysfunction, urinary
incontinence, chronic renal failure, sleep apnea, asthma, and
certain forms of cancer.
PCT"). This means it establishes an effective
filing date for inventions adequately described within it for PCT
applications or applications in more than 170 countries who are
members of the Paris Convention, as long as the foreign application
is filed within one year of the provisional filing date."
type="text">The U.S. provisional patent application provides a
right of priority under the Paris Convention as well as the Patent
Cooperation Treaty ("PCT"). This means it
establishes an effective filing date for inventions adequately
described within it for PCT applications or applications in more
than 170 countries who are members of the Paris Convention, as long
as the foreign application is filed within one year of the
provisional filing date.
About Translational Life Sciences Inc.
TLS is a contract research organization and a life
sciences company focused on developing proprietary formulations
that contain restricted substances for clinical applications to
serve unmet medical needs in the market. The TLS team is composed
of physicians and scientists who are recognized thought leaders in
the fields of Neurology, Pharmacology, Diabetes, Addiction and
Biochemistry and have significant experience in the clinical
application of cannabinoid compounds.
About NeonMind Biosciences Inc.
NeonMind is dedicated to the enhancement of human life
and wellness through the advancement of bioscience to engage the
mind to heal the body. It aims to be a leader in the fast-growing
functional and adaptogenic foods market, and is engaged in research
and the development of products and services using medicinal and
psychedelic mushrooms to heal the body through the mind. NeonMind
has filed a U.S. provisional patent applications to protect the
invention that the administration of psilocin and/or psilocybin
results in overall weight loss in individuals by reducing food
cravings, counteracting compulsive overeating, improving quality of
diet, increasing metabolism, treating diabetes, regulating blood
glucose and reducing susceptibility to cardiovascular disease, high
blood pressure, diabetes mellitus and other illnesses associated
with obesity. NeonMind owns 18% of Translational Life Sciences Inc.
Yield Growth owns approximately 68% of the issued and outstanding
stock of NeonMind.
About The Yield Growth Corp.
The Yield Growth Corp. (CSE: BOSS),(OTCQB: BOSQF) is a
phytoceutical and consumer packaged goods company that develops and
acquires intellectual property and other assets related to
plant-based products and therapeutics, and develops, manufactures,
markets, sells and distributes plant-based products that improve
lives. It has over 200 proprietary wellness formulas at various
stages of commercialization, including over 20 products that are
now for sale through e-commerce or brick and mortar retail stores.
It is currently launching several hand sanitizer products in
response to COVID-19. It has 14 patent applications filed in what
the Global Wellness Institute reports is a $4.2 trillion-dollar
global wellness market. Its majority owned subsidiary NeonMind
Biosciences Inc. is launching a line of medicinal mushroom products
and is developing intellectual property in the emerging area of
psychedelic medicine. The Yield Growth management team has deep
experience with global brands including Johnson & Johnson,
Procter & Gamble, Skechers and Aritzia.
Investor Relations
Contacts:
invest@yieldgrowth.com
Penny White, President & CEO
Kevan Matheson, Investor Relations
1-833-514-BOSS 1-833-514-2677
1-833-515-BOSS 1-833-515-2677
The Canadian Securities Exchange has not reviewed,
approved or disapproved the contents of this news release.
Cautionary Statement Regarding
Forward-Looking Statements
This press release
includes forward-looking information and statements (collectively,
"forward looking statements") under applicable Canadian securities
legislation. Forward-looking statements are necessarily based upon
a number of estimates, forecasts, beliefs and assumptions that,
while considered reasonable, are subject to known and unknown
risks, uncertainties, and other factors which may cause actual
results and future events to differ materially from those expressed
or implied by such forward-looking statements. Such risks,
uncertainties and factors include, but are not limited to: risks
related to the development, testing, licensing, brand development,
availability of packaging, intellectual property protection,
reduced global commerce and reduced access to raw materials and
other supplies do to the spread of the Coronavirus, the potential
for not acquiring any rights as a result of the patent application
and any products making use of the intellectual property may be
ineffective or the company may be unsuccessful in commercializing
them; and other approvals will be required before commercial
exploitation of the intellectual property can happen. Demand for
the company's products, general business, economic, competitive,
political and social uncertainties, delay or failure to receive
board or regulatory approvals where applicable, and the state of
the capital markets. Yield Growth cautions readers not to place
undue reliance on forward-looking statements provided by Yield
Growth, as such forward-looking statements are not a guarantee of
future results or performance and actual results may differ
materially. The forward-looking statements contained in this press
release are made as of the date of this press release, and Yield
Growth expressly disclaims any obligation to update or alter
statements containing any forward-looking information, or the
factors or assumptions underlying them, whether as a result of new
information, future events or otherwise, except as required by
law.
Yield Growth (CSE:BOSS)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Yield Growth (CSE:BOSS)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024
